生命科学资讯
生物技术与制药领域的最新动态
Lonza’s Strategic Pivot Fuels Robust Growth and Shareholder Returns - AD HOC NEWS
Hims因FDA反对取消销售复方GLP-1药丸计划
Hims cancels plans to sell compounded GLP-1 pill after FDA backlash
Hims因美国法律压力宣布停止销售GLP-1减肥药片。
Hims says it will stop selling GLP-1 pill, after legal pressure from US
#ACTRIMS26：赛诺菲公布托莱布替尼治疗原发性进展型多发性硬化症三期试验失败数据
#ACTRIMS26: Sanofi unpacks data from a failed Phase 3 tolebrutinib trial in PPMS
重新审视赛默飞世尔科技（TMO）估值，近期股价疲软后的新视角 - simplywall.st
Taking A Fresh Look At Thermo Fisher Scientific (TMO) Valuation After Recent Share Price Weakness - simplywall.st
安捷伦的SLAS2026自动化推进可能改变投资安捷伦科技（A）的理由 - simplywall.st
Agilent’s SLAS2026 Automation Push Might Change The Case For Investing In Agilent Technologies (A) - simplywall.st
Hims与诺和诺德的对决；辉瑞月度GLP-1数据发布；第四季度财报汇总；及其他动态
The Hims vs. Novo showdown; Pfizer’s monthly GLP-1 data; Q4 earnings roundup; and more
龙沙集团发布部分信息不明公告，细节模糊引关注——TipRanks
Lonza Issues Partially Unreadable Release, Leaving Details Unclear - TipRanks
Illumina (ILMN) 2025财年业绩后一次性收益塑造盈利叙事 - simplywall.st
Illumina (ILMN) One Off Gain Shapes Profitability Narrative After FY 2025 Earnings - simplywall.st
Illumina财报电话会议凸显临床增长势头 - TipRanks
Illumina Earnings Call Highlights Clinical Growth Momentum - TipRanks
美国呼吁司法部调查Hims公司涉及GLP-1药物问题
US calls for DOJ investigation of Hims over GLP-1 drugs
安捷伦科技公司（$A）CEO 2025年薪酬披露 - Quiver Quantitative
AGILENT TECHNOLOGIES, INC. ($A) CEO 2025 Pay Revealed - Quiver Quantitative
特朗普处方药计划启动遇冷，部分人指其普及性不足。
TrumpRx launch falls flat for some, citing generic access
关键数据：Illumina 2025年第四季度营收增至11.6亿美元；预计2026年增长前景 - TradingView
Key facts: Illumina Q4 2025 revenue rises to $1.16B; 2026 growth forecasted - TradingView
UniQure暂停两组法布里病基因疗法给药，因毒性问题显现。
UniQure pauses Fabry gene therapy dosing in 2 groups after toxicities emerge
新披露显示，罗氏基因泰克去年裁员至少489人。
Roche’s Genentech cut at least 489 jobs last year, new disclosure reveals
美国卫生与公众服务部放弃对受阻的340B折扣试点计划的法律诉讼。
HHS drops legal fight over blocked 340B rebate pilot
美国支出法案中的孤儿药调整将减轻FDA负担
Orphan drug tweak in US spending bill will make life easier for the FDA
白宫在线药品销售服务上线，对药价影响有限。
White House’s online service for drug sales debuts with limited impact on prices